In a statement, Sun Pharma said the US FDA on Monday informed that it will lift the Import Alert imposed on the Mohali manufacturing facility and remove the facility from the Official Action Initiated (OAI) status.
"This proposed action will clear the path for Sun Pharma to supply approved products from the Mohali facility to the US market, subject to normal US FDA regulatory requirements," Sun Pharma said.
The Mohali facility was inherited by Sun Pharma as part of its acquisition of Ranbaxy Laboratories Ltd. in 2015.
The US FDA had taken action against the Mohali facility in 2013.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)